CARDIFF ONCOLOGY INC (CRDF)
US14147L1089 - Common Stock
Overall CRDF gets a fundamental rating of 2 out of 10. We evaluated CRDF against 568 industry peers in the Biotechnology industry. While CRDF has a great health rating, there are worries on its profitability. CRDF is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CRDF had negative earnings in the past year.
CRDF had a negative operating cash flow in the past year.
CRDF had negative earnings in each of the past 5 years.
In the past 5 years CRDF always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -68.37%, CRDF is not doing good in the industry: 64.60% of the companies in the same industry are doing better.
CRDF has a Return On Equity of -87.07%. This is comparable to the rest of the industry: CRDF outperforms 49.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.37% | ||
| ROE | -87.07% | ||
| ROIC | N/A |
ROA(3y)-34.36%
ROA(5y)-49.48%
ROE(3y)-38.69%
ROE(5y)-72.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRDF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRDF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRDF remains at a similar level compared to 1 year ago.
CRDF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 2.33 indicates that CRDF is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.33, CRDF is in the better half of the industry, outperforming 72.21% of the companies in the same industry.
There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.33 |
ROIC/WACCN/A
WACC11.78%
2.3 Liquidity
CRDF has a Current Ratio of 4.74. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.74, CRDF is in line with its industry, outperforming 52.04% of the companies in the same industry.
A Quick Ratio of 4.74 indicates that CRDF has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.74, CRDF is in line with its industry, outperforming 53.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.74 | ||
| Quick Ratio | 4.74 |
3. Growth
3.1 Past
CRDF shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.17%.
CRDF shows a strong growth in Revenue. In the last year, the Revenue has grown by 49.78%.
CRDF shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.13% yearly.
EPS 1Y (TTM)-2.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
Revenue 1Y (TTM)49.78%
Revenue growth 3Y9.67%
Revenue growth 5Y5.13%
Sales Q2Q%17.02%
3.2 Future
The Earnings Per Share is expected to decrease by -17.82% on average over the next years. This is quite bad
CRDF is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -11.38% yearly.
EPS Next Y-9.24%
EPS Next 2Y-3.8%
EPS Next 3Y-10.43%
EPS Next 5Y-17.82%
Revenue Next Year60.98%
Revenue Next 2Y-6.2%
Revenue Next 3Y-28.58%
Revenue Next 5Y-11.38%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CRDF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDF. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CRDF's earnings are expected to decrease with -10.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.8%
EPS Next 3Y-10.43%
5. Dividend
5.1 Amount
CRDF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARDIFF ONCOLOGY INC
NASDAQ:CRDF (12/18/2024, 4:08:52 PM)
After market: 4.5 +0.01 (+0.22%)4.49
-0.86 (-16.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap229.57M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.37% | ||
| ROE | -87.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.74 | ||
| Quick Ratio | 4.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-2.17%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-9.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)49.78%
Revenue growth 3Y9.67%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y